Cargando…

Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study

Fifteen known type 2 diabetes (T2D) gene variants were assessed for their associations with T2D status in 228 T2D families from the Framingham Heart Study (FHS) Original, Offspring, and Children Cohorts. Bayesian approach was used to test single-single-nucleotide polymorphism (SNP) association follo...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Ping, Feitosa, Mary, Ketkar, Shamika, Adelman, Avril, Lin, Shiow, Borecki, Ingrid, Province, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795973/
https://www.ncbi.nlm.nih.gov/pubmed/20018066
_version_ 1782175483078639616
author An, Ping
Feitosa, Mary
Ketkar, Shamika
Adelman, Avril
Lin, Shiow
Borecki, Ingrid
Province, Michael
author_facet An, Ping
Feitosa, Mary
Ketkar, Shamika
Adelman, Avril
Lin, Shiow
Borecki, Ingrid
Province, Michael
author_sort An, Ping
collection PubMed
description Fifteen known type 2 diabetes (T2D) gene variants were assessed for their associations with T2D status in 228 T2D families from the Framingham Heart Study (FHS) Original, Offspring, and Children Cohorts. Bayesian approach was used to test single-single-nucleotide polymorphism (SNP) association followed by logistic regression. Bayesian and logic regression approaches were used to test multiple SNP association searching for the best combinations of variants followed by logistic regression reconfirmation. The significant variants for T2D risk were also tested for their main and interacting effects on triglyceride (TG)/high-density lipoprotein (HDL) ratio change derived from four point measures across time. This slope phenotype was made available using mixed model growth curve approach from 155 T2D families in the FHS Offspring Cohort. RESULTS: CDKN2B rs10811661 (p = 0.042), TCF7L2 rs4506565 (p = 0.004), and JAZF1 rs864745 (p = 0.04) were individually associated with risk of T2D (OR = 1.0-2.0; effect size <1%). CDKN2B and TCF7L2 were found with significant main (p = 0.02, 0.01) and interacting (p = 0.05) effects for increased (OR = 3.0) risk of T2D. CDKN2B and JAZF1 were found with significant main (p = 0.0002 and 0.034) and interacting (p = 0.001) effects on increased (β = 0.42) TG/HDL ratio longitudinal change. These interacting effects were independent of effects of age and sex with effect sizes of 0.3-0.4% for risk of T2D or TG/HDL ratio longitudinal change. CONCLUSION: These synthetic approaches allowed for successful detection of CDKN2B and TCF7L2 interacting effect for T2D risk and CDKN2B and JAZF1 interacting effect on TG/HDL ratio increase over time among T2D families in the FHS. These interacting effects were consistent in conferring risk of T2D or progressive insulin resistance with modest effect sizes.
format Text
id pubmed-2795973
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27959732009-12-18 Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study An, Ping Feitosa, Mary Ketkar, Shamika Adelman, Avril Lin, Shiow Borecki, Ingrid Province, Michael BMC Proc Proceedings Fifteen known type 2 diabetes (T2D) gene variants were assessed for their associations with T2D status in 228 T2D families from the Framingham Heart Study (FHS) Original, Offspring, and Children Cohorts. Bayesian approach was used to test single-single-nucleotide polymorphism (SNP) association followed by logistic regression. Bayesian and logic regression approaches were used to test multiple SNP association searching for the best combinations of variants followed by logistic regression reconfirmation. The significant variants for T2D risk were also tested for their main and interacting effects on triglyceride (TG)/high-density lipoprotein (HDL) ratio change derived from four point measures across time. This slope phenotype was made available using mixed model growth curve approach from 155 T2D families in the FHS Offspring Cohort. RESULTS: CDKN2B rs10811661 (p = 0.042), TCF7L2 rs4506565 (p = 0.004), and JAZF1 rs864745 (p = 0.04) were individually associated with risk of T2D (OR = 1.0-2.0; effect size <1%). CDKN2B and TCF7L2 were found with significant main (p = 0.02, 0.01) and interacting (p = 0.05) effects for increased (OR = 3.0) risk of T2D. CDKN2B and JAZF1 were found with significant main (p = 0.0002 and 0.034) and interacting (p = 0.001) effects on increased (β = 0.42) TG/HDL ratio longitudinal change. These interacting effects were independent of effects of age and sex with effect sizes of 0.3-0.4% for risk of T2D or TG/HDL ratio longitudinal change. CONCLUSION: These synthetic approaches allowed for successful detection of CDKN2B and TCF7L2 interacting effect for T2D risk and CDKN2B and JAZF1 interacting effect on TG/HDL ratio increase over time among T2D families in the FHS. These interacting effects were consistent in conferring risk of T2D or progressive insulin resistance with modest effect sizes. BioMed Central 2009-12-15 /pmc/articles/PMC2795973/ /pubmed/20018066 Text en Copyright ©2009 An et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Proceedings
An, Ping
Feitosa, Mary
Ketkar, Shamika
Adelman, Avril
Lin, Shiow
Borecki, Ingrid
Province, Michael
Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study
title Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study
title_full Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study
title_fullStr Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study
title_full_unstemmed Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study
title_short Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study
title_sort epistatic interactions of cdkn2b-tcf7l2 for risk of type 2 diabetes and of cdkn2b-jazf1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the framingham heart study
topic Proceedings
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795973/
https://www.ncbi.nlm.nih.gov/pubmed/20018066
work_keys_str_mv AT anping epistaticinteractionsofcdkn2btcf7l2forriskoftype2diabetesandofcdkn2bjazf1fortriglyceridehighdensitylipoproteinratiolongitudinalchangeevidencefromtheframinghamheartstudy
AT feitosamary epistaticinteractionsofcdkn2btcf7l2forriskoftype2diabetesandofcdkn2bjazf1fortriglyceridehighdensitylipoproteinratiolongitudinalchangeevidencefromtheframinghamheartstudy
AT ketkarshamika epistaticinteractionsofcdkn2btcf7l2forriskoftype2diabetesandofcdkn2bjazf1fortriglyceridehighdensitylipoproteinratiolongitudinalchangeevidencefromtheframinghamheartstudy
AT adelmanavril epistaticinteractionsofcdkn2btcf7l2forriskoftype2diabetesandofcdkn2bjazf1fortriglyceridehighdensitylipoproteinratiolongitudinalchangeevidencefromtheframinghamheartstudy
AT linshiow epistaticinteractionsofcdkn2btcf7l2forriskoftype2diabetesandofcdkn2bjazf1fortriglyceridehighdensitylipoproteinratiolongitudinalchangeevidencefromtheframinghamheartstudy
AT boreckiingrid epistaticinteractionsofcdkn2btcf7l2forriskoftype2diabetesandofcdkn2bjazf1fortriglyceridehighdensitylipoproteinratiolongitudinalchangeevidencefromtheframinghamheartstudy
AT provincemichael epistaticinteractionsofcdkn2btcf7l2forriskoftype2diabetesandofcdkn2bjazf1fortriglyceridehighdensitylipoproteinratiolongitudinalchangeevidencefromtheframinghamheartstudy